These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37787109)

  • 1. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
    John NA; Solanky BS; De Angelis F; Parker RA; Weir CJ; Stutters J; Carrasco FP; Schneider T; Doshi A; Calvi A; Williams T; Plantone D; Monteverdi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    J Magn Reson Imaging; 2024 Jun; 59(6):2192-2201. PubMed ID: 37787109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
    Solanky BS; John NA; DeAngelis F; Stutters J; Prados F; Schneider T; Parker RA; Weir CJ; Monteverdi A; Plantone D; Doshi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
    AJNR Am J Neuroradiol; 2020 Dec; 41(12):2209-2218. PubMed ID: 33154071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.
    Sastre-Garriga J; Ingle GT; Chard DT; Ramió-Torrentà L; McLean MA; Miller DH; Thompson AJ
    Arch Neurol; 2005 Apr; 62(4):569-73. PubMed ID: 15824254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered hypothalamic metabolism in early multiple sclerosis - MR spectroscopy study.
    Hnilicová P; Kantorová E; Poláček H; Grendár M; Bittšanský M; Čierny D; Sivák Š; Zeleňák K; Lehotský J; Dobrota D; Kurča E
    J Neurol Sci; 2019 Dec; 407():116458. PubMed ID: 31622679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans.
    Tisell A; Leinhard OD; Warntjes JB; Aalto A; Smedby Ö; Landtblom AM; Lundberg P
    PLoS One; 2013; 8(4):e61817. PubMed ID: 23613944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.
    Lind A; Boraxbekk CJ; Petersen ET; Paulson OB; Siebner HR; Marsman A
    J Neurosci; 2020 Oct; 40(42):8149-8159. PubMed ID: 32994337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy.
    Wattjes MP; Harzheim M; Lutterbey GG; Klotz L; Schild HH; Träber F
    AJNR Am J Neuroradiol; 2007 Sep; 28(8):1517-22. PubMed ID: 17846203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-voxel magnetic resonance spectroscopy of cerebral metabolites in healthy adults at 3 Tesla.
    Doelken MT; Mennecke A; Stadlbauer A; Kloska S; Struffert T; Engelhorn T; Thuerauf N; Doerfler A; Stefan H; Hammen T
    Acad Radiol; 2009 Dec; 16(12):1493-501. PubMed ID: 19781961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    Obert D; Helms G; Sättler MB; Jung K; Kretzschmar B; Bähr M; Dechent P; Diem R; Hein K
    PLoS One; 2016; 11(9):e0162583. PubMed ID: 27636543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolite changes in early relapsing-remitting multiple sclerosis. A two year follow-up study.
    Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; McLean MA; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
    J Neurol; 2006 Feb; 253(2):224-30. PubMed ID: 16307201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.
    Bustillo JR; Jones T; Chen H; Lemke N; Abbott C; Qualls C; Stromberg S; Canive J; Gasparovic C
    Schizophr Bull; 2017 May; 43(3):611-619. PubMed ID: 27550776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case control study: magnetic resonance spectroscopy of brain in HIV infected patients.
    Bairwa D; Kumar V; Vyas S; Das BK; Srivastava AK; Pandey RM; Sharma SK; Jagannathan NR; Sinha S
    BMC Neurol; 2016 Jul; 16():99. PubMed ID: 27405321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
    Abdel-Aziz K; Schneider T; Solanky BS; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Peters AL; Day BL; Thompson AJ; Ciccarelli O
    Brain; 2015 Jun; 138(Pt 6):1568-82. PubMed ID: 25863355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis.
    Fernando KT; McLean MA; Chard DT; MacManus DG; Dalton CM; Miszkiel KA; Gordon RM; Plant GT; Thompson AJ; Miller DH
    Brain; 2004 Jun; 127(Pt 6):1361-9. PubMed ID: 15128615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.
    Chard DT; Griffin CM; McLean MA; Kapeller P; Kapoor R; Thompson AJ; Miller DH
    Brain; 2002 Oct; 125(Pt 10):2342-52. PubMed ID: 12244090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.
    White TL; Monnig MA; Walsh EG; Nitenson AZ; Harris AD; Cohen RA; Porges EC; Woods AJ; Lamb DG; Boyd CA; Fekir S
    Neuropsychopharmacology; 2018 Jun; 43(7):1498-1509. PubMed ID: 29511334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.
    Sijens PE; Mostert JP; Oudkerk M; De Keyser J
    Eur Radiol; 2006 Feb; 16(2):489-95. PubMed ID: 16028056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue.
    Kantorová E; Poláček H; Bittšanský M; Baranovičová E; Hnilicová P; Čierny D; Sivák Š; Nosáľ V; Zeleňák K; Kurča E
    Neurol Res; 2017 Apr; 39(4):323-330. PubMed ID: 28191860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
    Connick P; De Angelis F; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S; Chataway J;
    BMJ Open; 2018 Aug; 8(8):e021944. PubMed ID: 30166303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.